BeyondSpring stock plunges after FDA says NDA for CIN treatment 'cannot be approved' in current form
Shares of BeyondSpring Inc. plunged 55.2% toward a record low in premarket trading Wednesday, after the biopharmaceutical company said that it has received a complete response letter (CRL) from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback